EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery

Xinya Yang, Baifeng Wang, Yucheng Zhang, Yinli Xie, Zhiyong Li, Peng Sun

Pharmaceuticals · 02.11.2026 · 19 (11) · 1741

DOI: 10.3390/ph19111741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 02.11.2026. Verfasst von Xinya Yang und 5 weiteren Autor:innen. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Plan of China, Ningbo Natural Science Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continuous emergence and re-emergence of viral pathogens pose persistent threats to global health. Although direct-acting antivirals (DAAs) have transformed the treatment of multiple viral infections, their spectrum is often constrained by viral diversity and the rapid emergence of drug resistance. Host-targeted antivirals (HTAs) provide a complementary strategy by targeting cellular processes exploited by diverse viruses, but their development is limited by host toxicity and context-dependent viral dependence. Here, we propose that antiviral breadth is not an intrinsic property of a drug or target but an emergent phenotype governed by four interconnected determinants: conservation of biological vulnerability, viral dependency, chemical tractability, and therapeutic selectivity. We examine how these determinants shape the antiviral spectrum of both virus- and host-directed strategies and discuss key translational barriers, including metabolic compensation, viral adaptation, and the gap between in vitro activity and in vivo efficacy. We further propose a mechanism-guided framework that integrates viral evolution, host dependency, pharmacological tractability, intracellular exposure, and rational combination strategies to enable more predictive broad-spectrum antiviral discovery. Rather than seeking a universal antiviral, this framework supports the development of modular therapeutic strategies tailored to viral dependency, tissue context, and pharmacological constraints.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Plan of China
  • Ningbo Natural Science Foundation
  • the Summit Advancement Disciplines of Zhejiang Province
  • Science Technology Department of Wenzhou

Zitieren

APA

Yang, X., Wang, B., Zhang, Y., Xie, Y., Li, Z., & Sun, P. (2026). Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery. Pharmaceuticals, 19(11), 1741. https://doi.org/10.3390/ph19111741

Vancouver

Yang X, Wang B, Zhang Y, Xie Y, Li Z, Sun P. Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery. Pharmaceuticals. 2026;19(11):1741. doi:10.3390/ph19111741

BibTeX
@article{Yang2026,
  author = {Yang, Xinya and Wang, Baifeng and Zhang, Yucheng and Xie, Yinli and Li, Zhiyong and Sun, Peng},
  title = {Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1741},
  doi = {10.3390/ph19111741}
}
Kostenlos starten →